Drug Index

Ustekinumab

 
print

Mechanism :

Human monoclonal antibody that binds to and interferes with the proinflammatory cytokines, interleukin (IL)-12 and IL-23.


Indication :

• Crohn’s disease

• Plaque psoriasis


Contraindications :

Clinically significant hypersensitivity to ustekinumab or any component of the formulation.


Dosing :

Plaque psoriasis:

Children ≥12 years and Adolescents:

<60 kg: 0.75 mg/kg SC at day 1 and then after 4 weeks, and then every 12 weeks thereafter.

≥60 kg to ≤100 kg: 45 mg SC at day 1 and then after 4 weeks, and then every 12 weeks thereafter.

>100 kg: 90 mg SC at day 1 and then after 4 weeks, and then every 12 weeks thereafter.


Adverse Effect :

Antibody development, Infection, Nasopharyngitis, Headache, fatigue, dizziness, Erythema at injection site.


Interaction :

BCG (Intravesical): Immunosuppressants may diminish the therapeutic effect of BCG (Intravesical).
Belimumab: Monoclonal Antibodies may enhance the adverse/toxic effect of Belimumab.
Infliximab: Ustekinumab may enhance the immunosuppressive effect of Infliximab.
Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.
Vaccines (Live): Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.


07/14/2019 20:12:35 Ustekinumab
ask a doctor
Ask a Doctor
Disclaimer: The information given by www.pediatriconcall.com is provided by medical and paramedical & Health providers voluntarily for display & is meant only for informational purpose. The site does not guarantee the accuracy or authenticity of the information. Use of any information is solely at the user's own risk. The appearance of advertisement or product information in the various section in the website does not constitute an endorsement or approval by Pediatric Oncall of the quality or value of the said product or of claims made by its manufacturer.
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0